890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alpelisib Neoplasm	Tianjin Medical University Second Hospital	P2	CCC (52)
Anastrozole Neoplasm	DR. DIANE CHISESI NFS. MD. PHD.	P2	CCC (52)
Anti-Pd-L1 Monoclonal Antibody Kn035 Neoplasm	3D Medicines (Sichuan) Co., Ltd.	P2	CCC (52)
Cmp 001 Neoplasm	Pfizer	P3	CCC (52)
Indocyanine Green Neoplasm	University of Pennsylvania	P1/2	CCC (52)
Ivuxolimab Neoplasm	Pfizer	P3	CCC (52)
Letetresgene Autoleucel Neoplasm	USWM CT, LLC	P2	CCC (52)
Lorlatanib Neoplasm	Pfizer	P3	CCC (52)
Microbubble Neoplasm	NaviFUS Corporation	P3	CCC (52)
Pemigatinib Neoplasm	UNICANCER	P2	CCC (52)
Pomalidomide Neoplasm	Hellenic Society of Hematology	P2	CCC (52)
Rifaldazine Neoplasm	Boehringer Ingelheim	P1	CCC (52)
Sirolimus Neoplasm	Albert Einstein College of Medicine	P2	CCC (52)
xnw5004 Neoplasm	Evopoint Biosciences Inc.	P1/2	CCC (52)
Hydroxychloroquine Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (51)
Senaparib Neoplasm	Impact Therapeutics, Inc.	P1	CCC (51)
Vismodegib Neoplasm	Helsinki University Central Hospital	P2	CCC (51)
Absk061 Neoplasm	Abbisko Therapeutics Co, Ltd	P2	CCC (50)
Aspirin Neoplasm	Val Adams	P2	CCC (50)
Atorvastatin Neoplasm	Joaquina Baranda	P2	CCC (50)
Autologous Cd1C+ /Cd141+ Mydc Neoplasm	Universitair Ziekenhuis Brussel	P2	CCC (50)
Avutometinib Neoplasm	Memorial Sloan Kettering Cancer Center	P2	CCC (50)
Azacytidine Neoplasm	Mohammed Milhem	P1	CCC (50)
Defactinib Neoplasm	University of Oklahoma	P2	CCC (50)
e-602 Neoplasm	Palleon Pharmaceuticals, Inc.	P1/2	CCC (50)
Ensartinib Neoplasm	Nanjing First Hospital, Nanjing Medical University	P2	CCC (50)
Envafolimab Neoplasm	3D Medicines (Sichuan) Co., Ltd.	P2	CCC (50)
Givastomig Neoplasm	I-Mab Biopharma US Limited	P2	CCC (50)
Hrs-4508 Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P2	CCC (50)
Inavolisib Neoplasm	Hoffmann-La Roche	P2	CCC (50)
Jab-21822 Neoplasm	Allist Pharmaceuticals, Inc.	P2	CCC (50)
Nirogacestat Neoplasm	Hellenic Society of Hematology	P1/2	CCC (50)
Sacituzumab Tirumotecan Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (50)
Si-B003 Neoplasm	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (50)
Tazemetostat Neoplasm	Prisma Health-Upstate	P2	CCC (50)
Technetium [99Mtc]-H7Nd Neoplasm	Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.	P2	CCC (50)
Tepotinib Neoplasm	Helsinki University Central Hospital	P2	CCC (50)
wx390 Neoplasm	Shanghai Jiatan Pharmatech Co., Ltd	P2	CCC (50)
Adagrasib Neoplasm	Mirati Therapeutics Inc.	P2	CCC (49)
Ascrinvacumab Neoplasm	Suzhou Kintor Pharmaceutical Inc,	P1/2	CCC (49)
Bms 986253 Neoplasm	Yana Najjar	P2	CCC (49)
dc05f01 Neoplasm	Heronova Pharmaceuticals	P1/2	CCC (49)
Entinostat Neoplasm	University Hospital Heidelberg	P1/2	CCC (49)
Tocilizumab Neoplasm	Hoffmann-La Roche	P1/2	CCC (49)
Valproic Acid Neoplasm	Miller Children's & Women's Hospital Long Beach	P1	CCC (49)
[18f]f-resca-rt4 Neoplasm	RenJi Hospital	P2/3	CCC (48)
[18F]F-RESCA-T4 Neoplasm	RenJi Hospital	P2/3	CCC (48)
[18f]rccb6 Neoplasm	RenJi Hospital	P2	CCC (48)
4scar-psma t cells Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (48)
[68ga]ga-nota-rt4 Neoplasm	RenJi Hospital	P2/3	CCC (48)

Showing 151 to 200 of 890 assets

PreviousPage 4 of 18Next